Arjuna Therapeutics

Executive Summary

Arjuna Therapeutics is a Barcelona-based biotechnology company founded in 2020, pioneering a novel class of small molecules called Therapeutic Molecular Clusters (TMCs). Its lead program, Ag5, is a cancer-mitochondrial-specific antioxidant deactivator designed to selectively induce oxidative stress in tumor cells while sparing healthy tissues. The company aims to extend survival in late-stage cancer patients and redefine the standard of care across solid tumors. With a unique mechanism targeting mitochondrial redox balance, Ag5 has the potential to address high unmet needs in oncology. Currently in Phase 1 clinical development, Arjuna is initiating first-in-human studies to evaluate the safety, tolerability, and pharmacokinetics of Ag5 in advanced solid tumors. The company is positioning itself for value inflection with upcoming data readouts and potential expansion into additional indications. Despite being early-stage, the novelty of TMCs and the strong scientific rationale behind Ag5 position Arjuna as a compelling player in the precision oncology space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and PK data readout60% success
• Q2 2026Presentation of preclinical data at major oncology conference90% success
• TBDPotential partnering discussions for Ag5 in combination therapies40% success